Nucleus Software Intrinsic Value
NUCLEUS • Information Technology
Current Stock Price
₹865.40
Primary Intrinsic Value
₹479.52
Market Cap
₹2250 Cr
-57.3%
Downside
Median Value
₹369.23
Value Range
₹260 - ₹584
Assessment
Trading Above Calculated Value
Safety Margin
-100.0%
NUCLEUS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹479.52 | ₹383.62 - ₹575.42 | -44.6% | EPS: ₹39.96, Sector P/E: 12x |
| Book Value Method | asset | ₹313.08 | ₹281.77 - ₹344.39 | -63.8% | Book Value/Share: ₹313.08, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹283.08 | ₹254.77 - ₹311.39 | -67.3% | Revenue/Share: ₹353.85, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹369.23 | ₹332.31 - ₹406.15 | -57.3% | EBITDA: ₹160.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹583.76 | ₹467.01 - ₹700.51 | -32.5% | CF Growth: 7.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹259.62 | ₹233.66 - ₹285.58 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹329.27 | ₹296.34 - ₹362.20 | -62.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹480.00 | ₹432.00 - ₹528.00 | -44.5% | ROE: 12.8%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹530.55 | ₹477.49 - ₹583.61 | -38.7% | EPS: ₹39.96, BVPS: ₹313.08 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
NUCLEUS Intrinsic Value Analysis
What is the intrinsic value of NUCLEUS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Nucleus Software (NUCLEUS) is ₹369.23 (median value). With the current market price of ₹865.40, this represents a -57.3% variance from our estimated fair value.
The valuation range spans from ₹259.62 to ₹583.76, indicating ₹259.62 - ₹583.76.
Is NUCLEUS undervalued or overvalued?
Based on our multi-method analysis, Nucleus Software (NUCLEUS) appears to be trading above calculated value by approximately 57.3%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 9.71 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 12.8% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.80x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Nucleus Software
Additional stock information and data for NUCLEUS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹151 Cr | ₹141 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹222 Cr | ₹124 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹50 Cr | ₹44 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹58 Cr | ₹58 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹115 Cr | ₹52 Cr | Positive Free Cash Flow | 7/10 |